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Over the past decade the cure rate in children with nonlocalised B cell non-Hodgkin's lymphoma (NHL) has improved due to a moderate intensification of drug dose and the introduction of high dose methotrexate with folinic acid rescue (Murphy et al., 1989) . Some groups of patients remain a therapeutic problem such as those with CNS disease at presentation or a leukaemia-like syndrome (Sariban et al., 1983; Murphy, 1980 (Murphy, 1980) . This can range from a localised abdominal tumour which is deemed unresectable on the grounds of a desire to avoid unnecessary intestinal resection rather than surgical feasibility, to a patient with extensive abdominal disease, with renal and splenic involvement and pleural effusions. It seems likely that, as in most solid tumours and haematological malignancies, initial disease bulk is of prognostic significance. Consequently, treatment for some patients with small volume disease may be excessively intensive, carrying the unneccessary risk of sterilisation and second tumours. Conversely, standard treatment will be inadequate for a subgroup with more extensive disease for whom further dose intensification, possibily including megatherapy and autologous bone marrow rescue may be indicated.
The It has been suggested (Philip et al., 1987) was given as an out-patient. By contrast, in MACHO there is considerable dose escalation with administration of high dose methotrexate between courses of myelosuppressive therapy. In-patients admission was required both for administration of treatment and for the almost inevitable treatment of febrile neutropaenic episodes.
From the outset of the study two protocols were recommended. Regimen 1 was designed for the majority of patients. Regimen 2 was a new high dose intensity protocol to be used by a limited number of centres for patients considered to be 'high risk'. This decision was due to a reluctance to continue using a less intensive regimen for patients with very bulky disease or multi-organ involvement. Unfortunately this clinical subdivision was subjective and moreover some centres were reluctant to use Regimen 2 in any children due to the anticipated morbidity.
Results
Complete remission (CR) was confirmed with X-ray, CT scan or ultrasound. Other imaging procedures such as bone scan were used where appropriate. In only two patients was initial surgical excision of the abdominal primary tumour attempted and radiotherapy was not used in any patients. Forty-one/44 patients achieved complete remission. In addition one of three patients who was an early toxic death was found to be in complete remission at autopsy. Due to the high chemosensitivity of this tumour and the often bulky disease, tumour lysis syndrome was anticipated. Abnormalities in renal function were apparent in seven patients despite hyperhydration and allopurinol. In one of these cases renal dysfunction was exacerbated by nodal obstruction of the ureters. Two patients, including the latter, required elective dialysis during induction and one patient was managed with haemofiltration. There were no deaths primarily due to tumour lysis syndrome although acute renal also in the testis. Two were in the central nervous system, of whom one also had ocular involvement and one disease in the orbit at relapse. The fifth relapsed in the orbit and the sixth in the mediastinum and lungs. As is characteristics of this disease, all relapses occurred early, namely 6, 5, 8, 5, 19 and 7 months after diagnosis.
The actuarial event free survival for the two regimens is shown in Figure 3 -1 it t-I 11 11 11-11
Time since diagnosis (Years) and methotrexate has had a dramatic impact on cure rates. However, the question as to whether there are sub-groups which require further intensification of therapy or, conversely, less intensive treatment cannot be answered by either the current study or previously published data. Inevitably, the numbers of patients are limited and most published series are small. Most protocols are based on a cyclophosphamide, anthracycline and methotrexate combination with a variety of additional agents. The overall disease-free survival at 2 years i.e. probable cure, range from 62% to 81%. The former figure was achieved with the LSA2L2 regimen which has been demonstrated in a previous randomised study to be inferior to the conventional CHOP-based regimen (Anderson et al., 1982) . The best results have been reported by the French 'LMB' group (Patte et al., 1986; Patte et al., 1990) and the St Judes group (Murphy et al., 1986) . Sub-group analysis in the LMB studies dividing patients on the basis of the extent of disease have confirmed the inferior outcome where organs beyond the intestine are involved, such as liver, spleen, reproductive organs or mediastinum, i.e., Lyon group B (Rodary et al., 1988) . It should be noted that some recent series have contained a disproportionate number of patients with more limited disease, explaining the good outcome (Finlay et al., 1989) .
Because investigators in the UKCCSG study were free to allocate children to either of two protocols it is impossible to draw conclusions as to the superior efficacy of the more intensive MACHO regimen. The outcome of patients with the less intensive regimen 1 was excellent although it is apparent that a smaller proportion of these patients had truly extensive multi-organ involvement. By contrast, the main reason for allocating children to regimen 2 was more extensive disease at presentation and hence there were a higher number of poor risk patients given the MACHO protocol.
Protocol 1 was based on traditional CHOP regimen with the addition of intermediate dose methotrexate and a combination of drugs shown to have efficacy in lymphoblastic leukaemia, namely low dose cytarabine, thioguanine and teniposide. The necessity for this many drugs is unclear and good results can be achieved using regimens based on only three drugs, namely cyclophosphamide, high dose methotrexate and vincristine, provided doses are high enough. In the MACHO regimen the number of drugs was reduced compared to regimen 1 but the dose increased following the strategy of Murphy et al. (1986) and the LMB group. Work with very high dose chemotherapy using autologous bone marrow rescue has confirmed the efficacy of dose escalation in advanced B cell lymphoma (Philip et al., 1985) . In the MACHO regimen the strategy of high dose intensity, with rapid drug delivery, is applied. There is increasing evidence that delivering bigger doses of chemotherapy in shorter periods of time will improve outcome (Dembo, 1987) . The administration of methotrexate 12-15 days after highly myelosuppressive chemotherapy was an unconventional approach which enabled the interval between exposure of tumour to active chemotherapeutic agents to be minimised.
With a tumour such as B cell NHL, where there is a high growth fraction tumour regrowth may recur during a 21-28 day gap between pulsed chemotherapy. With folinic acid rescue high dose methotrexate is non-myelosuppressive and can therefore be given despite low blood counts.
Inevitably the toxicity of the MACHO regimen was high with the risk of severe sepsis, mucositis, gastrointestinal problems and prolonged periods in hospital. This was due to the pulses of cyclophosphamide/doxorubicin and high dose cytarabine, not the high dose methotrexate. These complications are common to most modem intensive chemotherapy regimens and are the reason why it is essential to determine which patients with stage III disease may be spared such treatment.
The National Cancer Institute (NCI) has recently suggested subdividing stage III patients along the lines of the Lyon classification. NCI stage IIIA is 'unresected intraabdominal tumour and epidural tumour, not otherwise stage IV, i.e. no CSF blasts nor cranial nerve palsy'. IIIB is 'intra- and extra-abdominal tumour except bone marrow' (Magrath, 1989) . This system has not yet been clinically assessed. It is of note that although the presence of a pleural effusion has been said to be an adverse prognostic factor (Sandlund et al., 1990) this may not be the case in the absence of other extranodal disease.
Because in the present study patients were not randomly allocated to the more or less intensive regimens, firm conclusions cannot be drawn regarding who needs more therapy. It is likely that the tendency for investigators to allocate those with more bulky disease to regimen 2 probably improved the outcome in this group. Clarification of prognostic factors is urgently required.
In the current co-operative UKCCSG/SFOP (French Society of Paediatric Oncology) study all patients with stage IIIB cell NHL receive the LMB 84 regimen and prognostic factors are being evaluated prospectively. The latter include initial tumour bulk, serum LDH levels, response to first exposure to chemotherapy, time to achieve complete response and nutritional status at presentation. It is hoped that an answer will be reached in 3-5 years and the sub-group with a favourable outcome can then be considered for elective treatment with a less intensive regimen. Conversely, those with a poor prognosis will be treated with early megatherapy.
